title: Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.
abstract: The long-held belief that degeneration of the cholinergic basal forebrain was central to Alzheimer's disease (AD) pathogenesis and occurred early in the disease process has been questioned recently. In this regard, changes in some cholinergic basal forebrain (CBF) markers (e.g. the high affinity trkA receptor) but not others (e.g., cortical choline acetyltransferase [ChAT] activity, the number of ChAT and vesicular acetylcholine transporter-immunoreactive neurons) suggest specific phenotypic changes, but not frank neuronal degeneration, early in the disease process. The present study examined the expression of the low affinity p75 neurotrophin receptor (p75(NTR)), an excellent marker of CBF neurons, in postmortem tissue derived from clinically well-characterized individuals who have been classified as having no cognitive impairment (NCI), mild cognitive impairment (MCI), and mild AD. Relative to NCI individuals, a significant and similar reduction in the number of nucleus basalis p75(NTR)-immunoreactive neurons was seen in individuals with MCI (38%) and mild AD (43%). The number of p75(NTR)-immunoreactive nucleus basalis neurons was significantly correlated with performance on the Mini-Mental State Exam, a Global Cognitive Test score, as well as some individual tests of working memory and attention. These data, together with previous reports, support the concept that phenotypic changes, but not frank neuronal degeneration, occur early in cognitive decline. Although there was no difference in p75(NTR) CBF cell reduction between MCI and AD, it remains to be determined whether these findings lend support to the hypothesis that MCI is a prodromal stage of AD.
authors.affiliation: Department of Neurological Sciences, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. emufson@rush.edu
authors.forename: Elliott J
authors.initials: EJ
authors.lastname: Mufson
authors.forename: Shuang Y
authors.initials: SY
authors.lastname: Ma
authors.forename: John
authors.initials: J
authors.lastname: Dills
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Cochran
authors.forename: Sue
authors.initials: S
authors.lastname: Leurgans
authors.forename: Joanne
authors.initials: J
authors.lastname: Wuu
authors.forename: David A
authors.initials: DA
authors.lastname: Bennett
authors.forename: Syed
authors.initials: S
authors.lastname: Jaffar
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Gilmor
authors.forename: Alan I
authors.initials: AI
authors.lastname: Levey
authors.forename: Jeffrey H
authors.initials: JH
authors.lastname: Kordower
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology / Q000523:psychology; D020532:Basal Nucleus of Meynert / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D015984:Causality; D002452:Cell Count; D003072:Cognition Disorders / Q000378:metabolism* / Q000473:pathology / Q000523:psychology; D015536:Down-Regulation / Q000502:physiology*; D005260:Female; D005838:Genotype; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009474:Neurons / Q000378:metabolism* / Q000473:pathology; D009483:Neuropsychological Tests; D058225:Plaque, Amyloid / Q000473:pathology; D020800:Receptor, Nerve Growth Factor / Q000378:metabolism*
chemical_list: D020800:Receptor, Nerve Growth Factor; D000109:Acetylcholine